Medtronic wins expanded FDA approval for diabetic-friendly Resolute Integrity stent

February 25, 2013 by Arezu Sarvestani

U.S. healthcare regulators approved new sizes of Medtronic's Resolute Integrity drug-eluting stent to treat longer coronary lesions.

Medtronic's Resolute Integrity stent

Medical device giant Medtronic (NYSE:MDT) won expanded FDA approval for new sizes of its Resolute Integrity drug-eluting stent, the only devices of its kind with regulatory indication for treatment in patients with diabetes.

The new sizes allow for treatment of long coronary lesions, those which span more than 27mm, according to Medtronic.

"Long coronary lesions and diabetes represent 2 distinct but often interrelated clinical challenges," cardiologist Dr. Ronald Caputo said on behalf of the company. "The new sizes of the Resolute Integrity drug-eluting stent address both challenges in a single device. They have the potential to reduce procedure time and cost for clinicians and hospitals, as well as vessel trauma and contrast exposure for patients."

Sign up to get our free newsletters delivered right to your inbox.

Medtronic has been touring the Resolute Integrity stent in recent months, with a commercial launch in India in September 2012 and initial sales in Japan just a month before.